Literature DB >> 16775331

Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.

Amy L Hartman1, Jason E Dover, Jonathan S Towner, Stuart T Nichol.   

Abstract

The VP35 protein of Zaire Ebola virus is an essential component of the viral RNA polymerase complex and also functions to antagonize the cellular type I interferon (IFN) response by blocking activation of the transcription factor IRF-3. We previously mapped the IRF-3 inhibitory domain within the C terminus of VP35. In the present study, we show that mutations that disrupt the IRF-3 inhibitory function of VP35 do not disrupt viral transcription/replication, suggesting that the two functions of VP35 are separable. Second, using reverse genetics, we successfully recovered recombinant Ebola viruses containing mutations within the IRF-3 inhibitory domain. Importantly, we show that the recombinant viruses were attenuated for growth in cell culture and that they activated IRF-3 and IRF-3-inducible gene expression at levels higher than that for Ebola virus containing wild-type VP35. In the context of Ebola virus pathogenesis, VP35 may function to limit early IFN-beta production and other antiviral signals generated from cells at the primary site of infection, thereby slowing down the host's ability to curb virus replication and induce adaptive immunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775331      PMCID: PMC1488969          DOI: 10.1128/JVI.00044-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

Authors:  A Le Bon; G Schiavoni; G D'Agostino; I Gresser; F Belardelli; D F Tough
Journal:  Immunity       Date:  2001-04       Impact factor: 31.745

2.  The Ebola virus VP35 protein functions as a type I IFN antagonist.

Authors:  C F Basler; X Wang; E Mühlberger; V Volchkov; J Paragas; H D Klenk; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

3.  Ebola hemorrhagic fever and septic shock.

Authors:  Mike Bray; Siddhartha Mahanty
Journal:  J Infect Dis       Date:  2003-11-14       Impact factor: 5.226

4.  Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.

Authors:  Siddhartha Mahanty; Karen Hutchinson; Sudhanshu Agarwal; Michael McRae; Pierre E Rollin; Bali Pulendran
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

5.  Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice.

Authors:  T R Gibb; M Bray; T W Geisbert; K E Steele; W M Kell; K J Davis; N K Jaax
Journal:  J Comp Pathol       Date:  2001-11       Impact factor: 1.311

6.  Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus.

Authors:  M Bray; S Hatfill; L Hensley; J W Huggins
Journal:  J Comp Pathol       Date:  2001-11       Impact factor: 1.311

Review 7.  The interferon antiviral response: from viral invasion to evasion.

Authors:  Nathalie Grandvaux; Benjamin R tenOever; Marc J Servant; John Hiscott
Journal:  Curr Opin Infect Dis       Date:  2002-06       Impact factor: 4.915

8.  Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection.

Authors:  Thomas W Geisbert; Lisa E Hensley; Tom Larsen; Howard A Young; Douglas S Reed; Joan B Geisbert; Dana P Scott; Elliott Kagan; Peter B Jahrling; Kelly J Davis
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

9.  Phosphorylation of VP30 impairs ebola virus transcription.

Authors:  Jens Modrof; Elke Mühlberger; Hans-Dieter Klenk; Stephan Becker
Journal:  J Biol Chem       Date:  2002-06-06       Impact factor: 5.157

10.  The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.

Authors:  Christopher F Basler; Andrea Mikulasova; Luis Martinez-Sobrido; Jason Paragas; Elke Mühlberger; Mike Bray; Hans-Dieter Klenk; Peter Palese; Adolfo García-Sastre
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more
  57 in total

1.  The importance of the NP: VP35 ratio in Ebola virus nucleocapsid formation.

Authors:  Takeshi Noda; Larissa Kolesnikova; Stephan Becker; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

2.  Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function.

Authors:  Kathleen C Prins; Jennifer M Binning; Reed S Shabman; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

3.  Ebolavirus VP35 is a multifunctional virulence factor.

Authors:  Daisy W Leung; Kathleen C Prins; Christopher F Basler; Gaya K Amarasinghe
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

4.  Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.

Authors:  Megan R Edwards; Gai Liu; Chad E Mire; Suhas Sureshchandra; Priya Luthra; Benjamin Yen; Reed S Shabman; Daisy W Leung; Ilhem Messaoudi; Thomas W Geisbert; Gaya K Amarasinghe; Christopher F Basler
Journal:  Cell Rep       Date:  2016-02-11       Impact factor: 9.423

5.  Expression, purification, crystallization and preliminary X-ray studies of the Ebola VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Nathaniel D Ginder; Jay C Nix; Christopher F Basler; Richard B Honzatko; Gaya K Amarasinghe
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-01-31

6.  Filovirus replication and transcription.

Authors:  Elke Mühlberger
Journal:  Future Virol       Date:  2007-03       Impact factor: 1.831

7.  Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression.

Authors:  Christopher R Kimberlin; Zachary A Bornholdt; Sheng Li; Virgil L Woods; Ian J MacRae; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

8.  Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.

Authors:  Caroline G Williams; Joyce Sweeney Gibbons; Timothy R Keiffer; Priya Luthra; Megan R Edwards; Christopher F Basler
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

9.  Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35.

Authors:  Daisy W Leung; Kathleen C Prins; Dominika M Borek; Mina Farahbakhsh; JoAnn M Tufariello; Parameshwaran Ramanan; Jay C Nix; Luke A Helgeson; Zbyszek Otwinowski; Richard B Honzatko; Christopher F Basler; Gaya K Amarasinghe
Journal:  Nat Struct Mol Biol       Date:  2010-01-17       Impact factor: 15.369

10.  The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains.

Authors:  Ndongala M Lubaki; Philipp Ilinykh; Colette Pietzsch; Bersabeh Tigabu; Alexander N Freiberg; Richard A Koup; Alexander Bukreyev
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.